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Abstract
Background: Various histone acetylases (HATs) play a critical role in the regulation of gene
expression, but the precise functions of many of those HATs are still unknown. Here we provide
evidence that MYST4, a known HAT, may be involved in early mammalian gametogenesis.
Results: Although MYST4 mRNA transcripts are ubiquitous, protein expression was restricted to
select extracts (including ovary and testis). Immunohistochemistry experiments performed on
ovary sections revealed that the MYST4 protein is confined to oocytes, granulosa and theca cells,
as well as to cells composing the blood vessels. The transcripts for MYST4 and all-MYST4-isoforms
were present in oocytes and in in vitro produced embryos. In oocytes and embryos the MYST4
protein was localized in both the cytoplasm and nucleus. Within testis sections, the MYST4 protein
was specific to only one cell type, the elongating spermatids, where it was exclusively nuclear.
Conclusion: We established that MYST4 is localized into specialized cells of the ovary and testis.
Because the majority of these cells are involved in male and female gametogenesis, MYST4 may
contribute to important and specific acetylation events occurring during gametes and embryo
development.
Background
In eukaryotic cells, the tightly packed chromatin con-
tained in the nucleus directs fundamental cellular proc-
esses. The regulation of chromatin conformation by
specific structural proteins and their post-translational
modifications have a major influence on transcription,
repair, replication and recombination [1-5]. Histones are
important for chromatin organization and their residues
are constantly targeted by modification enzymes. One of
the modifications implicates acetylation of specific lysine
residues in core histones (H2A, H2B, H3 and H4). By its
ability to remodel chromatin, histone acetylation influ-
ences the transcriptional state of chromosomal regions by
controlling the accessibility of underlying genes, directly
linking this regulatory mechanism with gene activation
[6]. Acetylation of histones is also involved in the deposi-
tion of free histones onto newly synthesized DNA
[reviewed in [7]] and in the replacement of histones by
protamines [8]. Because histone acetylases (HATs) and
deacetylases (HDACs) are associated with crucial regula-
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tory roles, their dysregulation is often involved in diseases
such as cancer [9].
HATs are divided into 3 families: Gcn5/PCAF (general
control of amino-acid synthesis 5/p300-CBP-associated
factor), p300/CBP (Adenoviral E1A-associated protein/
CREB-binding protein) and MYST. Among these families,
MYST is more divergent and not as well characterized.
This protein family is also different with regard to domain
organization, multiprotein complex formation and bio-
logical function [10,11]. MYST is an acronym of its four
founding members: human MOZ (monocytic leukemia
zinc finger protein), yeast Ybf2 (renamed Sas3, for some-
thing about silencing 3), yeast Sas2, and mammalian
TIP60 (HIV Tat-interacting 60 kDa protein) [11]. MYST4,
also called MOZ2 or MORF (monocytic leukemia zinc fin-
ger protein-related factor), is a member of the MYST fam-
ily [12]. In vitro studies demonstrated that it preferentially
acetylates free histones H2A, H3 and H4, as well as nucle-
osomal H3 and H4. Alternative splicing variants are found
(MORF, MORFα and MORFβ), but their expression,
impact and function remain uncharacterized. The name
MYST4 is now attributed to the longest of the splicing var-
iant, MORFβ. The sequences composing some of MYST4's
domains are similar only to one other MYST family mem-
ber, MOZ. Both MOZ and MYST4 are involved in leuke-
mogenesis [13-15]. Chromosomal abnormalities found
in leukemia patients reveal that MYST4 is rearranged and
fused with the CBP  gene [13-15], a translocation also
associated with MOZ [16]. Additionally MYST4 can inter-
act with RUNX1 (Runt-related transcription factor 1), a
recurrent leukemia associated target [17]. In the mouse, its
homologue Querkopf is thought to be implicated in cell
differentiation in the cerebral cortex by regulating chro-
matin organization at some point during transcription.
The malformations found in the cerebral cortex of mutant
querkopf mice reveal that the gene is essential for normal
embryonic neurogenesis [18]. Its involvement in game-
togenesis and early embryogenesis is unknown, however
preliminary mRNA studies revealed that MYST4  tran-
scripts are present in high amounts in bovine oocytes (S.
McGraw, unpublished results) compared to other HATs
[19].
Many members of the MYST family have distinct domains
and diverse functions, including roles in epigenetic con-
trol, transcriptional regulation, DNA replication, DNA
repair, chromatin assembly, cell cycle progression and cel-
lular signalling (reviewed in [20]). It has been suggested
that MYST4 may also perform some of those functions,
although since it has unique domains it may act differ-
ently from other MYST members [17]. Structural features
found in MYST4 suggest that it could be a HAT with novel
properties. However, most functions and characteristics
attributed to MYST4 remain hypothetical and are only
based on sequence analysis. The lack of proteomic and
more thorough in vivo data are due to the absence of a
functional MYST4 antibody.
In the study presented here, our aim was to characterize
bovine MYST4 and the combination of all MYST4 splicing
variants simultaneously (MORF, MORFα, MORFβ) in var-
ious tissues, but more specifically in reproductive tissues
and gametes. The transcriptional study revealed that
MYST4 was ubiquitously expressed in bovine somatic tis-
sues. Unlike its mRNA, the MYST4 protein was present in
some, but not all, of the eleven somatic tissues tested. In
addition, MYST4 could be linked with important events
that take place during folliculogenesis, embryo develop-
ment, and spermatogenesis. MYST4  mRNA levels were
assessed in oocytes and embryos, as were protein expres-
sion and localization. Valuable information was addition-
ally obtained with the localization and expression of
MYST4 protein in the ovary and testis.
Results
MYST4 Sequence
Using polymerase chain reaction on oocyte cDNA, we
obtained an amplified fragment of approximately 6600
bp (not shown). Sequencing revealed that it corresponded
to the full-length bovine MYST4 gene. This splicing vari-
ant is the longest of the three MYST4 isoforms and
encoded 2054 amino acid residues (Fig. 1A). The three
splicing variants contained exactly the same sequences,
except that MORF and MORFα are 292 aa and 109 aa
shorter than MYST4 (MORFβ) (Fig. 1B). Alignment anal-
ysis also revealed that conservation between human and
bovine MYST4 was nearly 95%. The human MYST4
sequence has 19 more amino acids, which can be found
almost entirely in two glutamic acid-rich areas located in
its acidic region. Bovine MYST4 contains various struc-
tural domains throughout its coding sequence. The most
homologous domains were similar to those found in
other proteins such as linker histones H1/H5, PHD zinc
fingers and MYST histone acetylases (Fig. 1A). Addition-
ally acidic and Ser/Met-rich regions were found. A tran-
scriptional activation domain was also present in the C-
terminal sequence of MYST4.
MYST4 mRNA in Somatic Tissues
We assessed the presence of transcripts for MYST4 and for
all MYST4 isoforms simultaneously (MORF, MORFα and
MORFβ) by RT-PCR analysis in different bovine tissue
samples, including brain, thymus, muscle, lung, heart,
liver, kidney, spleen, testis, ovary, uterus and oocyte. The
three splicing variant sequences were similar except for
the gap present in MORF  and  MORFα  compared to
MYST4 (Fig. 1B) which was restrictive for designing prim-
ers. Individual analysis using the different sets of primers
for the splicing variants resulted in no or nonspecificBMC Developmental Biology 2007, 7:123 http://www.biomedcentral.com/1471-213X/7/123
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amplification of MORF and MORFα, therefore they could
not be investigated. Amplicons of expected sizes were gen-
erated for MYST4 and all-MYST4-iso, as well as for the
housekeeping gene TUBULIN (Fig. 2). The mRNA tran-
scripts for MYST4 and all-MYST4-iso were present in all
tissues tested. Although this was not a quantitative analy-
sis, the amplifications for the thymus, spleen, testis and
uterus gave more intense bands with the same amount of
cycles/cDNA compared to the other samples with both
the  MYST4  and all-MYST4-iso primers. However, the
amplifications from the oocytes samples were amongst
the most intense with the all-MYST4-iso primers, whereas
they were ones of the lowest detected with the MYST4
primers.
MYST4 Protein in Somatic Tissues
In order to characterize the distribution of MYST4, an
antibody was raised against a peptide specific only to
MYST4 and its isoforms. The same tissues that were used
for mRNA transcript analysis were subjected to Western
blotting. As shown in Fig. 3, one positive protein band of
about 230 kDa associated to MYST4 was predominantly
present in the lung, spleen and ovary, whereas the same
protein was also present but faintly detected in the brain,
testis, uterus and oocytes. In the heart a single sharp band
of about 200 kDa was detected. This protein is presuma-
bly the MORF isoform, which has a calculated molecular
weight of 197 kDa. Peptide-blocking assays established
that our MYST4 antibody was specific for the MYST4 pep-
Representation of Bovine MYST4 Figure 1
Representation of Bovine MYST4. A) Domain organization of MYST4. H15, linker histones H1- and H5-like domain; PHD, 
plant homeodomain zinc finger; C2HC, zinc finger; MYST HAT, conserved HAT domain characteristic of MYST family mem-
bers; Acidic, glutamate/aspartate-rich region; SM-rich, serine/methionine-rich domain. MYST4 is composed of 2054 residues in 
which the N-terminal region and the SM-rich domain encode transcriptional repression and activation domains respectively. B) 
Schematic illustration of MYST4 showing the alternative MYST4 splicing variants MORF and MORFα. Conserved regions 
between either 2 or 3 sequences are highlighted in gray and black respectively. Regions used for MYST4 primer designs are 
underlined in blue (forward) and in red (reverse). The number of residues in each sequence is indicated on the right. (Acces-
sion numbers: MYST4; [GenBank; XM_867653], MORF; [GenBank; XM_615480], MORFα; [GenBank; XM_880818])BMC Developmental Biology 2007, 7:123 http://www.biomedcentral.com/1471-213X/7/123
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tide used for antibody production since the single distinct
band disappeared (not shown). β-ACTIN was used as a
loading control, but since some tissue extracts lacked this
specific isoform, the samples were additionally probed
with an anti-TUBULIN antibody.
MYST4 Immunohistochemistry in Ovary
Since our Western blot experiments revealed that only a
portion of the strong MYST4 signal in the ovary was asso-
ciated with oocytes, immunolocalization experiments
were performed on ovary sections to distinguish which
other cell types expressed MYST4. In these tissue sections,
MYST4 expression was confined to follicles and to blood
vessels, as there was no other signal within the stroma. A
closer look at primordial follicles (Fig. 4A) revealed that
MYST4 was intensely expressed in the cytoplasm of the
oocyte, whereas the nucleus remained negative. MYST4
was also present in the cytoplasm of the simple squamous
epithelium layer surrounding the oocyte, while cells in the
proximity of the follicle wall were negative. In larger folli-
cles, like those at the antral stage, granulosa cells adjacent
to the oocyte and those covering the inside of the follicle
strongly expressed MYST4 (Fig. 4C). The oocytes con-
tained within these follicles displayed MYST4 in both
RT-PCR analysis of MYST4 mRNA Figure 2
RT-PCR analysis of MYST4 mRNA. Bovine MYST4 and all-MYST4-iso mRNA expression was investigated in different tis-
sues. From left to right, Br, brain; Th, thymus; Mu, muscle; Lu, Lung; He, heart; Li, liver; Ki, kidney; Sp, spleen; Te, testicle; Ov, 
ovary; Ut, uterus; Oo, germinal vesicle stage oocytes; Ne, PCR negative control. Amplification of TUBULIN is shown as an inter-
nal control.
Western blot analysis of MYST4 protein Figure 3
Western blot analysis of MYST4 protein. Protein extracts were subjected to SDS-PAGE and blotted onto nitrocellulose 
before being probed with an anti-bovine MYST4. From left to right, Br, brain; Th, thymus; Mu, muscle; Lu, Lung; He, heart; Li, 
liver; Ki, kidney; Sp, spleen; Te, testicle; Ov, ovary; Ut, uterus; Oo, germinal vesicle stage oocytes. TUBULIN and β-ACTIN 
antibodies were incubated simultaneously on the same membrane and were used as control.BMC Developmental Biology 2007, 7:123 http://www.biomedcentral.com/1471-213X/7/123
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their cytoplasm and nucleus (Fig. 4C). In large follicles
MYST4 was not only present in granulosa cells, but also
on the other side of the basal lamina, in the theca cells
(Fig. 4E). While essentially all granulosa cells expressed
MYST4 in their cytoplasm, only a portion of theca cells
expressed MYST4. Within the theca cell population posi-
tive for MYST4, the majority displayed a strong signal for
this protein in their nucleus, however a faint signal was
also observed in some cell cytoplasm. Additionally ovary
sections revealed that cells composing blood vessels also
expressed MYST4 in their cytoplasm (Fig. 4G).
MYST4 mRNA Profiles in Oocytes and Embryos
The mRNA profiles for MYST4 and all MYST4 isoforms
(simultaneously) were assessed in oocytes and through-
out bovine in vitro embryo culture by quantitative RT-
PCR. The MYST4 variant and all-MYST4-iso exhibited a
similar overall mRNA profile in oocytes and throughout
early embryo development (Fig. 5). The highest relative
levels of MYST4 mRNA were found in immature GV and
mature MII oocytes. Transcript levels measured in the
oocyte stages as well as in the 2- and 4-cell stages did not
differ significantly, but a significant reduction was
observed in the 8-cell embryos. The relative mRNA levels
Quantification of MYST4 and all-MYST4-iso in bovine oocytes  and early embryos using real-time RT-PCR Figure 5
Quantification of MYST4 and all-MYST4-iso in bovine 
oocytes and early embryos using real-time RT-PCR. 
Each developmental stage was analyzed in triplicate using 0.5 
oocyte or embryo per reaction. The relative mRNA levels 
shown represent the quantity of transcript corrected for the 
GFP value obtained for each pool. The highest level was 
attributed the relative value of 100. Shown is the relative 
mRNA abundance (mean ± SEM). Different letters indicate a 
significant difference of relative mRNA abundance (P < 0.05).
Ovarian localization of MYST4 protein by immunohistochem- istry Figure 4
Ovarian localization of MYST4 protein by immuno-
histochemistry. Ovarian sections showing: primordial folli-
cles (A, B); antral stage follicle, arrowhead showing oocyte 
nuclei (C, D); portion of large antral follicles, arrowheads 
indicating granulosa cells (right), theca (down) and basal lam-
ina (left) (E, F) and blood vessels (G, H). Positive sections 
were incubated with anti-MYST4 (A, C, E, G,) and negatives 
were prepared by peptide-blocking assay (B, D, F, H). Origi-
nal magnifications: 200× (C, D, E, F, G, H) and 400× (A, B).BMC Developmental Biology 2007, 7:123 http://www.biomedcentral.com/1471-213X/7/123
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were lowest in 8-cell, 16-cell and morula embryos but
tended to increase in blastocysts (Fig. 5A).
The relative levels of all-MYST4-isoforms were also at their
highest intensity in both oocyte stages studied (Fig. 5B).
Thereafter, significant decreases were observed in 2-, 4-, 8-
and 16-cell embryos. The transcript levels for the com-
bined isoforms were lowest in 16-cell and morula
embryos. These minimal levels were subsequently fol-
lowed by a significant increase in transcripts at the blasto-
cyst stage.
MYST4 Immunocytochemistry in Oocytes and Embryos
To evaluate the localization of MYST4 protein in bovine
oocyte and embryo, immunolocalization experiments
were performed on unfertilized bovine oocyte and
throughout  in vitro embryo development (Fig. 6). The
immature oocyte strongly expressed MYST4 in its germi-
nal vesicle (oocyte nucleus) and uniformly in its ooplasm
(Fig. 6A). As the oocyte resumes its maturation, the GV
breaks down (GVBD) and no nuclear membrane is notice-
able at the metaphase I (MI) stage of meiosis. At that
moment, MYST4 was not present on the chromatin but
appeared to concentrate on the mitotic spindle and scat-
tered in the ooplasm (Fig. 6B). In the in vitro matured
oocyte (MII), MYST4 remained present throughout the
ooplasm and along condensed chromosomes (Fig. 6C),
but the first expulsed polar body did not reveal any stain-
ing (Fig. 6D). During the subsequent cleavage stages, in 2-
, 4-, 8- and 16-cell embryos, MYST4 was clearly expressed
in the cytoplasm (Fig. 6E, F, G and 6H). However, nuclear
localization during that period in blastomeres was not as
obvious compared to GV oocytes. Compact morula
embryos exhibited a similar MYST4 expression profile in
the cytoplasm and nucleus (Fig. 6I). In early and expand-
ing blastocysts, MYST4 was observed in both the cyto-
plasm and nucleus of cells composing the trophectoderm
and inner cell mass (Fig. 6J and 6K). However, the stain-
ing intensities of the nuclei were not similar, with some
showing strong signal whereas it was weaker or absent in
Localization of MYST4 in oocyte and early embryo development Figure 6
Localization of MYST4 in oocyte and early embryo development. Confocal representation of oocytes (GV, MI and 
MII) or embryos (2-, 4-, 8-, 16-cell, morula, early blastocyst and blastocyst) stained with an anti-MYST4 antibody (green signal) 
and with propidium iodide (red signal) to visualize the DNA. Original magnification 600×.BMC Developmental Biology 2007, 7:123 http://www.biomedcentral.com/1471-213X/7/123
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others (Fig. 6J and 6K). For all stages, negative controls
were performed with a peptide-blocking assay, of which
an example is shown (Fig. 6L).
MYST4 Immunohistochemistry in Testis
To establish if MYST4 expression in testis could also be
restricted to specific cell types, testis sections were immu-
nostained with the MYST4 antibody (Fig. 7). In the first
cross-section (Fig. 7A), MYST4 was only present in some
seminiferous tubules whereas others did not show any
staining. This strongly suggests that its expression is devel-
opmentally regulated and is stage-specific during sperma-
tid differentiation (spermiogenesis). MYST4 appeared to
localize in cells facing the lumen of the seminiferous
tubules and was cell-specific during spermiogenesis. To
investigate this hypothesis, seminiferous tubules at differ-
ent stages of spermatogenesis were closely observed (Fig.
7C to 7K). The spermatid differentiation process in bovine
is divided in 14 described steps that include round (steps
1–7), elongating (steps 8–12) or elongated spermatids
(steps 12–14) [21]. These various spermatids, from steps
1–12, are distributed in a specific manner within the sem-
iniferous tubules (additional file 1). The seminiferous
tubules are also divided into classes, called stages (I to
XII), accordingly to the seminiferous epithelium cycle.
Additionally, diverse types of germ cells (spermatogonia
and spermatocytes) are distributed inside the different
stages of the seminiferous epithelium cycle [21]. In sem-
iniferous tubules containing primary spermatocytes and
round spermatids (Fig. 7C &7D), which correspond to
stage VII of the seminiferous epithelium cycle, no MYST4
was detected. However, in seminiferous tubules cross-sec-
tions at stages VIII to XI, intense staining of the MYST4
protein was detected in elongating spermatids (Fig. 7F). At
higher magnification, the image clearly revealed that only
the heads (nucleus), and not the mid-sections, of elongat-
ing spermatids were stained by MYST4 antibody (Fig. 7G).
In this section (Fig. 7F and 7G), MYST4 immunolocaliza-
tion was clearly restricted to elongating spermatids, as no
spermatocytes were stained. Further along spermatogene-
sis, in stages IV to VI of the seminiferous epithelium cycle,
the elongated spermatids displayed no immunoreactivity
to MYST4 (Fig. 7I). The elongated spermatid nuclei
located on the inner wall facing the lumen as well as those
inside the lumen were negative for MYST4 (Fig. 7J).
Discussion
As a result of its unique structural domain organization as
well as its presence in various multisubunit complexes
[11], MYST4 is probably involved in the regulation of a
variety of biological processes. Although it is established
that MYST4 is a potent histone H3 and H4 acetylase [12],
the functional consequences of this enzymatic activity
remain unknown. Its specific function as a HAT remains
ambiguous, but its involvement in chromosomal abnor-
malities found in leukemia patients [14,15,22] and its
normal presence in neurogenesis development have
already been established [18,23]. In this paper we aimed
to characterize MYST4 and the combination of all MYST4
isoforms simultaneously (MORF, MORFα, MORFβ) in
various tissues, but more specifically in reproductive tis-
sues and in gametes.
Based on its sequence, the bovine MYST4 protein is highly
similar to its human counterpart, with almost 95%
homology. Bovine MYST4 contains the same structural
domains that make MYST4 so unique and therefore we
can assume that bovine and human MYST4 take part in
the same cellular processes.
Expression of MYST4
A previous report revealed that human MORF is ubiqui-
tously expressed in somatic tissues [12]. Transcript levels
were high in tissues like heart, pancreas, testis and ovary,
whereas they were barely detectable in the lung. In our
study, we determined that the mRNA transcripts for the
MYST4 gene as well as for all MYST4 isoforms were also
ubiquitously present in all tissues tested, with different
intensities.
Because the mRNA transcripts for the different splicing
variants were present in each tissue tested, we thought
they would parallel the protein levels. However, MYST4
protein detection was quite variable in the same tissues,
ranging from high (lung, spleen and ovary) to undetecta-
ble (thymus, muscle, liver and kidney). Surprisingly, only
one of the tissues (heart) revealed a specific band with a
different molecular weight compared to the other tissues.
Protein extracts from the heart displayed only one band
which may be the shortest isoform, MORF.
MYST4 in female gametogenesis
Oocytes also expressed the MYST4 protein, albeit weakly,
and thus could not account for the important levels found
in the ovary extracts, suggesting that other cell types could
express MYST4. Immunolocalization on ovary sections
confirmed this by revealing that MYST4 was expressed in
follicular cells (granulosa and theca) enclosing the oocyte,
as well as in blood vessels. Although this is the first time
that the MYST4 acetylase is associated with folliculogene-
sis, various acetylation events occur within granulosa and
theca cells during follicle formation and growth. Numer-
ous experiments using ChIP (Chromatin immunoprecip-
itation) assays on these cells revealed that specific histone
acetylation events in the promoter region of ovarian genes
are affected by the increase in reproductive hormones
(reviewed in [24]). In vitro culture of rat granulosa cells
treated with FSH (follicle-stimulating hormone) enhances
the transcriptional activation of the SGK (serum-glucocor-
ticoid kinase) and the FOS (FBJ osteosarcoma oncogene)BMC Developmental Biology 2007, 7:123 http://www.biomedcentral.com/1471-213X/7/123
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Testicular localization of MYST4 protein by immunohistochemistry Figure 7
Testicular localization of MYST4 protein by immunohistochemistry. Testicular sections showing seminiferous 
tubules (A, B), containing mostly: primary spermatocytes and round spermatids (C, D, E), round spermatids and elongating 
spermatids (F, G, H), round spermatids and elongated spermatids (I, J, K). Images D, G, K are enlargements of boxed sections 
in C, F, I respectively. In magnified sections, arrowheads indicate: round spermatocyte (D), nucleus (left) and tail (up) of an 
elongating spermatid (G) and nuclei of elongated spermatids located in inner (up) wall and inside (left) of the lumen (J). Positive 
sections were incubated with anti-MYST4 (A, C, D, F, G, I, J) and negatives were prepared by peptide-blocking assay (B, E, H, 
K). Original magnification 1000× (A, B).BMC Developmental Biology 2007, 7:123 http://www.biomedcentral.com/1471-213X/7/123
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genes by increasing the acetylation of specific lysine resi-
dues on histone H3 [25]. In addition, granulosa cells
obtained from monkeys treated with hCG and from
human IVF (in vitro fertilization) patients also treated with
hCG exhibited histone H3 acetylation in the regulatory
regions of the StAR (steroidogenic acute regulatory pro-
tein) gene [26]. Furthermore, inhibition of HDACs in cul-
tured human theca cells increased total histone H3 and
H4 acetylation levels, along with mRNA transcription for
CYP11A (cytochrome P450, family 11, subfamily A,
polypeptide 1) and CYP17 (cytochrome P450, family 17)
[27]. Given that the MYST4 proteins are restricted to cer-
tain specialized cells in the ovary and have a strong his-
tone H3/H4 acetylation activity, they could regulate the
transcription of specific genes during folliculogenesis. The
functions of MYST4 in follicular cells may be somewhat
distinctive since the protein is mainly nuclear in theca
cells and cytoplasmic in granulosa cells. Dormant oocytes
enclosed in primordial follicles also lacked MYST4 in their
nucleus, but the oocytes contained in the larger follicles
exhibited MYST4 in both cytoplasm and nucleus. Since
dormant oocytes are deficient in transcription at this
point [28] they may not require this HAT in their nucleus
for regulatory processes, whereas growing oocytes are in a
transcriptionally active state and thus necessitate enzymes
responsible for chromatin remodeling.
Related mRNA profiles in oocytes and throughout
embryo development were observed between MYST4 and
all-MYST4-iso. However, since higher levels of transcripts
were measured with the all-MYST4-iso in oocytes com-
pared to the subsequent embryo stages, whereas MYST4
was equally present in the first four stages, we assume that
the splicing variants MORF  and/or  MORFα  are more
abundant in the GV and MII oocytes compared to other
embryo stages. Globally, a significant amount of all-
MYST4-iso transcripts was lost following each embryo
division up to the 16-cell stage, followed by a slight
increase in mRNA levels between morula and blastocyst
embryos. High levels of transcripts in oocytes could be
mRNA accumulated during oocyte growth and translated
into protein in subsequent stages of development until
the embryo is able to produce its own mRNA at the MET
(maternal embryonic transition). However the immu-
nolocalization study, although not quantitative, revealed
that similar intensity of staining for cytoplasmic MYST4
was found throughout development. This could indicate
that the protein has an extensive half-life or the transcripts
produced by post-MET embryos are constantly being
translated into new proteins and do not accumulate.
Interestingly, GV oocytes contained the largest measured
levels of MYST4 transcripts and had the highest accumu-
lation of the protein in its nucleus. Since there is still some
active transcription in GV oocytes [29], MYST4 may
potentially be implicated in this permissive chromatin
state by co-regulating transcriptional complexes via its
transcriptional activation domain. Surprisingly, during
oocyte maturation when chromosomes are lined up along
the equator at the metaphase-1 stage, MYST4 was located
in the vicinity of the meiotic spindle rather than on chro-
mosomes. Interaction with chromatin is expected, since
MYST4 contains a H1/H5 domain that mediates self-asso-
ciation and interaction with core histones and the nucleo-
somes [11]. Because there is no nuclear membrane during
MI in meiosis, there was no barrier to retain MYST4 at this
location. Therefore it may be implicated in the meiotic
spindle action to separate the chromosomes or in other
related mechanisms. It is unlikely that it acetylates his-
tones H3 and H4 at that point, since histones are globally
deacetylated in oocytes during meiosis [30] and improper
histone deacetylation in the course of meiosis is associ-
ated with aneuploidy and embryo death [31]. Alterna-
tively, the α-TUBULIN proteins composing the
microtubules could perhaps be a target for MYST4, since
they are acetylated at different points in meiotic and
mitotic divisions in mouse oocytes [32]; however, no
studies have yet examined if MYST4 could acetylate α-
TUBULIN. Although MYST4 appeared to be present in the
nucleus from the 2-cell until the 16-cell stage embryo, no
major accumulation was observed in the nucleus. In the
morula and blastocyst stages, some nuclei appeared to
have the same accumulation as that observed in oocytes.
This nuclear accumulation may be associated to specific
stages in the cell cycle and since there are more individual
cells in those embryos, the chances of detecting this accu-
mulation are increased. The presence of MYST4 in the
nucleus also coincides with the activation of specific genes
involved in the delineation of the blastocyst inner cell
mass and trophectoderm [33].
MYST4 in male gametogenesis
Since MYST4 was linked with reproductive cells in the
ovary, we wondered if its presence in testis could have a
similar function. Surprisingly, in this organ, MYST4 was
restricted to specific cells. The antibody brightly stained
only the nucleus of elongating spermatids found in stages
VIII to XI of the seminiferous epithelium cycle, which nor-
mally enclose step-8 through -11 spermatids [21]. The
spermatid differentiation process in bovine is divided in
14 described steps that include round (steps 1–7), elon-
gating (steps 8–12) or elongated spermatids (steps 12–
14) [21,34]. The adjacent seminiferous tubules of the
same testis section, containing spermatids at different
stages of development, were not immunoreactive.
Because there are various nuclear modification events that
occur during spermiogenesis, MYST4 may be a key player
in one of them. In the nucleus of elongating spermatids at
different stages, important acetylation processes occur to
ensure proper histone displacement for their replacement
by transition proteins and protamines [35-37]. DuringBMC Developmental Biology 2007, 7:123 http://www.biomedcentral.com/1471-213X/7/123
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these processes, different residues of the core histones
(H3, H4, H2A and H2B) are targets for acetylation. In
mouse spermiogenesis, there are 16 reported steps, with
steps 9 to 12 associated with the elongating spermatids
[38]. Acetylation of histone H3 is limited to steps 10 and
11, whereas histone H4 is hyperacetylated from steps 8 to
11. For both H3 and H4, the intense staining seems
homogeneously distributed over the nuclear region. Fur-
thermore, the four potential sites of acetylation on his-
tone H4 (Lys 5, 8, 12, and 16) were individually studied
with specific antibodies and revealed to be all immunore-
active in steps 8 to 11 of the elongating spermatids [36].
Other acetylation events on histones H2A (steps 9 to 11)
and H2B (steps 10 and 11) are also observed in elongating
spermatids. To date, the only genes thought to be associ-
ated with histone H4 hyperacetylation in elongating sper-
matids prior to the histone-to-protamine exchange are all
members of the Cdy (chromodomain protein, Y chromo-
some)-related family [38,39]. In the mouse, where two
transcripts evolved for that gene, both cdyl (Cdy-like) and
cdyl2 exhibit a ubiquitous, long transcript as well as a
highly abundant, testis-specific short transcript [39]. In
human, members include the CDYL and CDYL2 genes
which are ubiquitously express in tissues, and CDY which
is an abundant testis-specific gene [39]. CDY  and its
homologs encode a HAT that acetylates free histones H4
and H2A [38]. By immunolocalization, it was shown that
mouse Cdyl is abundantly expressed in the nuclei of elon-
gating spermatids at the time histone H4 is hyper-
acetylated [38]. Although our immunolocalization
experiments were not performed on individual elongating
step sections, we could clearly distinguish that MYST4 was
also only present in elongating spermatids during sperma-
togenesis. Furthermore, MYST4 is not only able to
acetylate free H2A, H3 and H4 when used as substrates,
but can efficiently acetylate nucleosomal histones as well
[12]. With the new data obtained in our study added to
previous reports on MYST4, strong evidence connects this
protein with H2A, H3 and H4 acetylation during spermio-
genesis. However, because some of the histone modifica-
tions mentioned above are also present at some other
stages like spermatogonia and preleptotene spermato-
cytes, histone acetylases other than those of the CDY and
MYST4 families are likely to be involved in spermatogen-
esis.
MYST4 in vivo characteristics
Although MYST4 was discovered several years ago, it has
never been linked to the formation of a stable multisubu-
nit HAT complex. Recently, MYST4 and its close relative
MOZ (monocytic leukemia zinc finger) were character-
ized as part of a histone H3 specific HAT complex impor-
tant for DNA replication [40]. This HAT complex also
includes a member of the tumor suppressor family (ING5,
inhibitor of growth 5), proteins usually associated with
chromatin (BRPF 1/2/3) and an uncharacterized protein
homologous to a subunit of a yeast acetyltransferase
(Eaf6, Esa1-associated factor-6). Since this complex was
only able to acetylate H3K14 in HeLa cells [40], it is
unlikely to be involved in the acetylation of H4 in sperma-
tids. However, transcripts from related BRFP family mem-
bers are preferentially expressed within spermatocytes in
the testis [41,42] and in oocytes [42], suggesting that
BRFP proteins may be present and associated with MYST4
in other HAT complexes.
Although  MYST4  knock-outs are not yet available to
determine whether the gene is essential in reproduction or
other important processes, a mutant mouse for its
homolog querkopf exists. The homozygous querkopf mice
display about 10% of the normal coding mRNA com-
pared to wild type [18]. These mutant mice show cranio-
facial abnormalities, retarded postnatal growth, defects in
the central nervous system [18] and severe problems in
adult neurogenesis [23]. These physiological failures are
caused by the essential function attributed to Querkopf in
neural stem cells [18,43] and in bone formation through
its involvement with RUNX1 [17,44]. Because there is still
partial expression of wild-type querkopf mRNA, these mice
are still able to develop despite all their defects. However
for the moment, no information about other malforma-
tions or problems in folliculogenesis, spermatogenesis or
embryo development was reported for the homozygous
mutant mice. Even though MYST4 and MOZ interact in
different protein complexes, they specifically regulate
diverse stem cell populations [11,17,40]. Through its
complete deletion in mice, Moz revealed itself as an essen-
tial regulator of hematopoietic stem cell maintenance
[18,45]. Compared to the Querkopf or MYST4 mutants,
MOZ-null mice die before or at birth.
Conclusion
The work presented here reveals novel properties for the
histone acetylase MYST4. The data and conclusions from
bovine MYST4 will undoubtedly apply to the human pro-
tein since both sequences show extensive similarities. In
addition to providing the first proteomic study of this
poorly studied protein, this is the first report to link
MYST4 with early gametogenesis. To our knowledge,
MYST4 is the only HAT to be described in cells (elongating
spermatids, oocyte, granulosa and theca cells) related to
gamete formation in both male and female. The availabil-
ity of a highly specific and functional antibody will now
allow the use of techniques such as pull-down assay and
chromatin immunoprecipitation, to identify protein com-
plexes and isolate chromatin target sites associated with
MYST4 in transcriptional regulation events in reproduc-
tive tissues and other specific cell types. This antibody willBMC Developmental Biology 2007, 7:123 http://www.biomedcentral.com/1471-213X/7/123
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also provide a new tool to study the implication of MYST4
in acute myeloid leukemia (AML).
Methods
Unless otherwise stated, all materials were obtained from
Sigma-Aldrich (St. Louis, MO).
Oocyte Recovery and In Vitro Embryo Production
The procedures for oocyte recovery and in vitro embryo
production have been described previously [46]. Using
this culture system, more than 30% of inseminated
oocytes routinely reached the blastocyst stage. Briefly,
cumulus-oocyte complexes (COCs) were recovered from
bovine slaughterhouse ovaries, matured in modified syn-
thetic oviduct fluid (SOF) for 24 hrs, then transferred and
fertilized in a modified Tyrode lactate medium. Following
fertilization, putative zygotes were mechanically stripped
of their cumulus cells, washed in PBS and transferred to
modified SOF medium for embryo development. The 2-,
4-, 8-, and 16-cell embryos were collected at 36, 48, 72,
and 108 hrs post-insemination, respectively, whereas
morulae and blastocysts were collected after 6 and 8 d of
development. At each stage, all embryos were washed 3
times in PBS, collected in pools of 20, frozen and stored at
-80°C until RNA extraction. All oocyte and embryo pools
used for RNA extractions were collected and analyzed in
triplicates.
RNA Extraction and cDNA Preparation
For oocyte and embryo RNA extraction and cDNA prepa-
ration, GFP RNA was used as an external control [47,48].
Ten pg of exogenous GFP RNA containing a poly-A tail
[46] was added to each pool of oocytes and embryos prior
to RNA extraction. RNA extractions of the oocyte or
embryo pools containing GFP RNA were then performed
using the PicoPure RNA isolation kit (Arcturus/Molecular
Devices Corporation, Sunnyvale, CA) and directly used
for cDNA preparation as previously described [46].
Total RNA from bovine tissues was extracted using TriZol
Reagent (Invitrogen, Burlington, ON, Canada) according
to the manufacturer's protocol. All RNA extracts used were
treated with RNase-free DNase (Promega, Nepean, ON,
Canada). cDNA synthesis was performed using Omnis-
cript reverse transcriptase (Qiagen, Mississauga, ON, Can-
ada) with 600 ng of total RNA and oligo-d(T)12–18, as
described by the manufacturer.
Polymerase Chain Reaction (PCR)
Primers for all the genes analyzed are listed in Table 1 and
were designed using bovine sequences when possible, or
from a consensus derived from human and mouse
sequences. The primers for MYST4  were designed in a
region specific to this variant (Fig. 1B), whereas the prim-
ers for all-MYST4-iso were designed in a downstream area
common to all variants (not shown). Real-time PCR was
performed on a Lightcycler apparatus (Roche Diagnostics,
Laval, QC, Canada) using SYBR Green incorporation as
previously described [47]. Briefly, for each gene, a stand-
ard curve consisting of purified PCR product was included
in the run. Each of the PCR reactions was performed using
the equivalent of 0.5 oocyte/embryo. The annealing tem-
peratures for each set of primers are listed in Table 1. The
PCR products were separated by agarose gel electrophore-
sis and sequenced. GFP mRNA was used as an external
control to account for experimental errors due to tech-
niques involved or materials used for RNA extraction and
reverse transcription [46,47].
Standard PCR reactions (MYST4, all-MYST4-iso and
TUBULIN) were performed using cDNA equivalent to 1
oocyte or 1 µl of first strand cDNA for somatic tissues, and
Taq  Gold polymerase (Applied Biosystems, Streetsville,
ON, Canada) for 35 cycles as described by the manufac-
turer. For PCR amplification of the MYST4  complete
sequence, the cDNA equivalent to 5 oocytes was used with
Taq Advantage 2 (Clontech, Mountain View, CA) follow-
ing the manufacturer's indications.
Western Blotting
Proteins from brain, thymus, muscle, lung, heart, liver,
kidney, spleen, testis, ovary, and uterus were extracted on
ice in triple lysis buffer (50 mM Tris-HCl pH 7.6, 150 mM
NaCl, 0.02% NaN3, 0.1% SDS, 1% NP40, 0.5 % deoxy-
Table 1: Primers used for RT-PCR experiments.
Gene Primer sequences Accession numbers Length of PCR products (bp) TM (°C)
MYST4 (complete sequence) Up 5'-ATGTTCTTTCACCCGAATGC-3' AF119231 6590 55
Low 5'-AAATAAATGGTGCCAACAAATG-3' NM_017479
MYST4 Up 5'-AGTTCACAAAAGTCCAGCAC-3' AF119231 300 60
Low 5'-GCTAGAGGAGGAGGAGTGAG-3' XM_880782
all-MYST4-iso Up 5'-ACCTTCAGCCTTGCCAAACTG-3' AF119231 296 60
Low 5'-TCTTTGGCTGTGAGAGATGC-3'
TUBULIN Up 5'-CTCTGCTGAGAAAGCCTACCA-3' BC018948 400 60
Low 5'-CCACGTACCAGTGAACAAAGG-3'BMC Developmental Biology 2007, 7:123 http://www.biomedcentral.com/1471-213X/7/123
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cholic acid and protease inhibitors [Roche]) as previously
described [47]. Bovine oocytes (n = 100) were denuded,
washed in PBS then frozen at -80°C. Fifteen µg of each
extract or 100 oocytes were lysed in 2× SDS loading buffer
containing 6% β-mercaptoethanol at 95°C for 5 min. Pro-
teins were resolved on standard 6% SDS-PAGE gels and
transferred onto nitrocellulose membranes (Osmonics,
Minnetonka, MN) using a semi-dry transfer apparatus
(BioRad, Hercules, CA). Blotted membranes were blocked
in TBST (25 mM Tris-HCl pH 7.6, 125 mM NaCl and 0.1%
Tween-20) containing 5% ECL Advance Blocking Agent
(Amersham Biosciences, Piscataway, NJ) for 1 hr at room
temperature. Membranes were then incubated with a
1:7500 dilution of MYST4 antibody with 3% ECL Advance
Blocking Agent in TBST overnight at 4°C. This purified
anti-MYST4 was raised in rabbits against a 15-mer KLH-
conjugated peptide (YGGLDGKGAPKYPSC) which is spe-
cific to bovine MYST4 (AgriSera AB, Vännäs, Sweden). The
membranes were washed 1 × 15 min and 4 × 5 min in
TBST, then incubated with a peroxidase-conjugated anti-
body (Molecular Probes, Burlington, ON, Canada)
diluted 1:200,000 in TBST-3% ECL Advance Blocking
Agent for 45 min. Finally, membranes were washed 4 × 5
min in TBST followed by a 1 × 15 min wash in TBS before
the chemiluminescent signal was revealed using ECL
Advance Reagent (Amersham). To assess anti-MYST4 spe-
cificity, a peptide-blocking assay was carried out following
the manufacturer's recommendations. The same protocol
was used with the β-ACTIN antibody (Cell Signaling Tech-
nology Inc., Danvers, MA) and the α-TUBULIN antibody
(Sigma). Briefly, 15 µg of each extract were resolved on a
15% gel. A 1:10,000 dilution of β-ACTIN and 1:250,000
of α-TUBULIN antibodies were simultaneously incubated
with the blotted membrane before being probed with the
peroxidase-conjugated secondary antibody.
Immunocytochemistry
Oocytes and embryos used for the immunocytochemistry
experiments were obtained using the same method men-
tioned above. Immature germinal vesicle (GV) oocytes
and mature metaphase II (MII) oocytes, 1-, 2-, 4-, 8-, 16-
cell embryos, morulae and blastocysts, were fixed and per-
meabilized on poly-lysine slides as previously described
[47] using 2% paraformaldehyde for 30 min at RT. After
blocking in TBST-5% milk, the MYST4 antibody (1:1000
in wash solution containing 3% dry milk) was added. The
cells were subsequently washed and incubated with a flu-
orescein-conjugated goat anti-rabbit IgG (Molecular
Probes) diluted 1:1000 in wash solution with 3% dry
milk, washed again and incubated with propidium iodide
in PBS (final concentration of 10 µg/mL) for 10 min. Neg-
ative controls were prepared with either the fluorescein-
conjugated goat anti-rabbit IgG or with pre-immune
serum derived from the same rabbit that produced the
anti-MYST4. To assess anti-MYST4 specificity in oocytes
and embryos, a peptide-blocking assay was carried out fol-
lowing the manufacturer's recommendations. The fluo-
rescein-conjugated goat anti-rabbit IgG controls were
used to set the background fluorescence.
Immunohistochemistry
Testis and ovary samples were fixed in Bouin fixation
solution and mounted in paraffin blocks as described pre-
viously [49]. Briefly, non-specific sites were blocked with
1% BSA in PBS. The slides were incubated for 2 hrs at RT
in the presence of anti-MYST4 (1:500), and tissue sections
were then covered with a goat anti-mouse IgG coupled to
biotin for 1 hr at RT. After carefully washing the slide,
streptavidin-HRP was deposited on tissues for 30 min at
room temperature and the immune complex was then
revealed using 3,3'-diaminobenzidine (DAB). The slides
were mounted in mowiol (Calbiochem, La Jolla, CA) and
observed by light microscopy. For both ovary and testis,
negative controls were carried out by peptide-blocking
assay following the manufacturer's recommendations.
Statistical Analysis
The level of mRNA for each gene subjected to statistical
analysis was normalized using the GFP external control
[46-48]. The value obtained for each gene, within each
pool of cDNA, was divided by the value obtained for GFP
in the same cDNA pool. Data are presented as mean ±
SEM. Statistically significant differences in mRNA levels
between each developmental stage were calculated by pro-
tected ANOVA (SAS Institute, Cary, NC), and treatment
and replicate were included in the model. Differences
were considered statistically significant at the 95% confi-
dence level (P < 0.05).
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